Otsuka Backs Up Tolvaptan Data In Polycystic Kidney Disease
Executive Summary
Further top-line results from a Phase III study have been promising, and the US FDA will have to decide if the previously rejected polycystic kidney additional indication for tolvaptan is now firmly supported by safety and efficacy data.
You may also be interested in...
Keeping Track: Good News/Bad News For Pfizer; Filings For Brexanolone, Risankizumab
The latest US drug development news and highlights from our Performance Tracker.
Pipeline Watch: Top-Line Ozanimod, Romosozumab, Cariprazine Phase III Results
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.